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those that can stabilize DNA topoisomerase cleavable complex to stop the progression of DNA
process, may be very useful in cancer chemotherapy. In the ﬁeld of antituor DNA-intercalating
agents, 9-aminoacridine-4-carboxamide derivatives play an important role due to their anti-prolif-
erative properties. In the present study, 9-aminoacridine-4-carboxamide derivatives were designed,
synthesized, characterized and evaluated against lung cancer (A-549) cell line and cervical cancer
(HeLa) cell line in vitro by MTT assay. Compounds 5a, 5b and 5e were selected for anticancer eval-
uation against the lung cancer cell line and cervical cancer cell line. Compound 5b showed the max-
imum activity against the cervical cancer (HeLa) cell line with CTC50 (47.50 lg/ml) and compound
5e showed the maximum activity against the lung cancer (A-549) cell line with CTC50 (100 lg/ml)
among the tested compounds. The present study opens new vista for DNA intercalating anticancer
compounds and their further in vivo investigation.
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lsevier1. Introduction
The limited understanding of the mechanism involved in the
development of drug resistance poses a major obstacle in the de-
sign and development of anticancer agents. This has a serious
impact on the successful treatment of hematological
malignancies. Understanding the phenomenon of multidrug
resistance in tumor cells may help in the design of compounds
that could be selectively cytotoxic for the resistant cells
(Roninson et al., 1984). The great majority of antitumor agents
in the present clinical use are thought to exert their cytotoxic
action by interfering with DNA metabolism, some binding
60 P. Kumar et al.non-covalently and reversibly to DNA and exerting their action
either by inhibition of nucleic acid synthesis or by inhibition of
DNAbreakage and repair phenomenon (Baguley, 1982). In case
of this nature, the DNA minor grove appears to be a potential
site for the binding of a variety of agents and where antitumor
activity is initiated. The binding energy is being contributed by
ionic interactions, ion-dipole, ion-induced dipole interaction
and speciﬁc hydrogen bonding either to thymidine 2-keto oxy-
gen acceptor or guanine 2-amino donors (Baguley, 1982). The
design of molecules that recognize speciﬁc sequence of the
DNA double helix or those that can stabilize DNA topoisomer-
ase cleavable complex to stop the progression of DNA pro-
cesses, may be useful in cancer chemotherapy (Bodley and
Liu, 1988; Zahir et al., 1996; Helene, 1988).
The ﬁrst acridine based therapeutic agent speciﬁcally de-
signed for cancer treatment was developed during 1970’s. Acri-
dine has been clinically utilized as a single agent or in
combination with other anti neoplastic drugs in the treatment
of acute non-lymphocytic, lymphocytic and acute myeloid leu-
kemia. Acridine derivatives possessing fungicidal, anti-para-
sitic, antimicrobial, antitumor, anti-inﬂammatory, analgesics
etc. activities are well documented in literature (Sondhi et al.,
2005; Kumar et al., 2009; Auparakkitanon et al., 2003; Tomar
et al., 2010; Petrikaite et al., 2007).
The 9-aminoacridine-4-carboxamide is a structure of interest
to medicinal chemists and appears in many biologically active
compounds mostly with anticancer application. In the ﬁeld of
antitumor DNA-intercalating agents, 9-aminoacridine-4-car-
boxamide derivatives play an important role due to their anti-
proliferative properties. Several cancer chemotherapeutics such
as DACA have been developed as anticancer agents (Ma et al.,
2008; Atwell et al., 1984). The ﬁrst goal of this study was to syn-
thesize a new 9-aminoacridine-4-carboxamide derivative by
modiﬁed Ullmann–Goldberg reaction. Synthesis starting from
the reaction of o-chlorobenzoic acid with anthranilic acid in
the presence of copper (acts as catalyst) and copper oxide (acts
as co-catalyst) to give compound (1). Cyclization of (1) was done
with concentrated sulfuric acid to give 9-oxoacridan-4-carbox-
ylic acid (2). Some sulfonated impurities may be present in com-
pound (2), was puriﬁed by dissolving in ethanol and then
acidiﬁed with glacial acetic acid to give product (2) after thor-
ough cooling. Chlorination of (2) was done with freshly distilled
thionyl chloride to give 9-chloroacridine-4-carbonyl chloride
(3). The residual traces of thionyl chloride were removed by
extracting it with dry dichloromethane. Compound (3) was re-
acted with isopropylamine in dry and cooled dichloromethane
to give n-(isopropyl)-9-chloro acridine-4-carboxamide (4). This
compound (4) was dissolved in phenol and allowed to react with
substituted aromatic amine to give ﬁnal products (5a–5g) under
nitrogen atmosphere. The synthesized compounds were puriﬁed
by extracting the products with ethanol and diethyl ether and re-
crystallized with methanol/ethylacetate solution. Another goal
of this studywas to investigate the cell growth inhibitory activity
of selected newly synthesized derivatives on human small cell
lung cancer (A-549) cell line and human endothelial cervical can-
cer (HeLa) cell line in vitro by MTT assay.
2. Experimental
All chemicals used were of reagent grade and puriﬁed as per
the need of the reaction. Progress of the reaction was moni-tored by TLC using chloroform:methanol (10:1) system. 3-
(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT), fetal bovine serum (FBS), phosphate buffered saline
(PBS), Dulbecco’s modiﬁed eagle’s medium (DMEM) and
trypsin were obtained from Sigma–Aldrich Co., St Louis,
USA. EDTA, glucose and antibiotics from Hi-Media Labora-
tories Ltd., Mumbai, dimethyl sulfoxide (DMSO) and propa-
nol from E. Merck Ltd., Mumbai, India were obtained
Scheme 1.
2.1. Characterization
Melting points (mp) were determined using Veego micropro-
cessor based programmable melting point apparatus, in open
capillaries and are uncorrected. 1H NMR spectra were
recorded on a BRUKER AVANCE II 400 NMR spectropho-
tometer. All experiments were carried out in d6-DMSO, CDCl3
as solvent and 1H chemical shift of the solvent was used as a
secondary reference and referred to the TMS signal from the
usual relationship; the values of the chemical shift (d) are given
in ppm. IR spectra were taken using a PERKIN ELMER spec-
trophotometer over the range of 450–4000 cm1 in KBr tab-
lets. Molecular mass of the compounds was determined by
mass spectroscopy using a Micromass, Q-Tof micro (Water
make) spectrophotometer.2.2. Synthesis
2.2.1. Synthesis of N-(2-carboxyphenyl)anthranilic acid (1)
2.2.1.1. Modiﬁed UllMann–Goldberg reaction. A mixture of
o-chlorobenzoic acid 3.7 g (0.0233 mol), anthranilic acid 6.4 g
(0.046 mol), anhydrous sodium acetate 3.0 g, copper powder
0.15 g, copper oxide 0.075 g, DMF 25 ml was reﬂuxed for
4 h at 140–150 C. The mixture was allowed to stand at room
temperature for 10–15 min and the reaction mixture was
poured into 200 ml of water. Green color precipitate was
formed, the pH of the solution checked and if necessary, made
acidic with conc. HCl. The precipitate was ﬁltered and washed
with hot water thoroughly. The collected precipitate was dis-
solved in aqueous sodium hydroxide solution and heated with
activated charcoal and ﬁltered. and acidiﬁed with conc. HCl.
An yellow colored precipitate was formed and ﬁltered and
again washed with hot water, dried in an oven for 15–25 min
at 70–80 C. Yield 71%, mp 294–296 C.2.2.2. Synthesis of 9-oxoacridan-4-carboxylic acid (2)
A mixture of N-(2-carboxyphenyl)anthranilic acid
(0.008 mol) and concentrated sulfuric acid (6 ml) was heated
on a water bath for 4 h and cooled, then poured into ice
cooled water. The precipitated solid was collected and
washed well with hot water. This was dissolved in dilute
aqueous sodium hydroxide solution and following ﬁltration
was diluted with equal volume of EtOH and then acidiﬁed
with glacial acetic acid (this left any sulfonated impurities
in the solution). The acridone acid that slowly crystallized
from hot solution was collected after thorough cooling
(about 4-8 h stored in refrigerator) and washed with dilute
aqueous EtOH and dried, providing a pure product. Yield
78%, mp >300 C.
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Scheme. 1 (a) Sodium acetate, Cu, CuO and DMF, heating at 140–150 C for 4 h. (b) Cyclization by H2SO4 on water bath. (c) SOCl2,
two drops of DMF (d) Dry CH2Cl2, isopropylamine, 0–5 C. (e) Phenol heating at 100 C with primary aromatic amine.
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A suspension of 9-oxoacridan-4-carboxylic acid 2 g in freshly
distilled SOCl2 (6 ml) containing DMF (two drops) was heated
gently under reﬂux with stirring until homogeneous and then
was reﬂuxed for a further 45 min. The solution was evaporated
to dryness in vacuo below 40 C, and residual traces of SOCl2
were removed by the addition of dry CH2Cl2 and complete re-
evaporation of all solvent to give the crude product as yellow
powder. Product obtained can be used without further puriﬁ-
cation in next step. Yield 96%.
2.2.4. Synthesis of N-(isopropyl)-9-chloroacridine-4-
carboxamide (4)
An ice cold solution of isopropyl amine 1.61 ml (0.0187 mol) in
dichloromethane (10 ml) was added within 5 min to a stirring
ice cold suspension of (0.002 mol) of 9-chloroacridine-4-car-
bonylchloride in dichloromethane (10 ml) at 0–5 C. The
resulting solution was stirred at room temperature for another
2 h, washed twice with (40 ml) 10% sodium carbonate and
then with (40 ml) brine, and ﬁnally dried over anhydrous so-
dium sulfate. After removal of the solvent in vacuo, the prod-
uct was obtained as oil, which slowly solidiﬁed. This wasextracted with hot dry benzene and pet. ether (1:5) and ﬁltered
quickly. Crystalline material rapidly separated and addition of
further pet. ether completed the precipitation of the product.
The yellow solid was collected, and washed with pet. ether
and dried to give N-(isopropyl)-9-chloroacridine-4-carboxam-
ide as the product. Yield 90%, mp 140 C. IR (KBr) cm1
mmax: 3182, 3045, 2964, 1653, 1616, 1551, 1454, 1160, 1022,
747. 1H NMR (400 MHz, CDCl3): 11.66–1165(d, 1H, NH–
C‚O), 9.05–9.04(d, 1H, Ar), 8.59–8.57(d, 1H, Ar), 8.44–
8.42(d, 1H, Ar), 8.11–8.09(d, 1H, Ar), 7.90–7.86(t, 1H, Ar),
7.77–7.75(t, 1H, Ar), 7.69–7.67(t, 1H, Ar), 4.47–4.42(m, 1H,
–CH), 1.48–1.25(d, 6H, 2-CH3).
2.2.5. Synthesis of 4, 9-substituted acridine derivatives (5a–5g)
2.2.5.1. General procedure. N-(Isopropyl)-9-chloroacridine-4-
carboxamide (0.001 mol) was dissolved in phenol at 100 C
for 1 h under a nitrogen atmosphere and allowed to react with
aromatic amine (0.001 mol) under reﬂux for another 2 h. The
reaction was monitored by TLC. After completion of the reac-
tion, cooling down to room temperature, the residue was dis-
solved in ethanol (5 ml) and then poured into diethyl ether.
The deposit was collected by ﬁltration on Buckner funnel
62 P. Kumar et al.and washed with diethyl ether. The residue obtained was dried
at 70–80 C in an oven for 10–15 min. Recrystallized with
methanol/ethylacetate. The precipitate was ﬁltered and washed
with ethyl acetate. Dried for 10–15 min.
2.2.5.2. N-(Isopropyl)-9-[(30-triﬂouromethyl)phenylamino)
acridine-4-carboxamide hydrochloride (5a). 0.124 ml
(0.001 mol) of 3-aminobenzotriﬂouride was reacted with 0.3 g
(0.001 mol) of N-(isopropyl)-9-chloroacridine-4-carboxamide
to give a yellow product. Yield 88%, mp 208–214 C. IR
(KBr) cm1 mmax: 3402, 3222, 3051, 2973, 2929, 1619, 1566,
1446, 1167, 1131, 833, 748, 696, 650. NMR (400 MHz, d6-
DMSO): 15.39 (s, 1H, NH+), 12.68 (s, 1H, NH), 9.35–9.33
(d, 1H, NH–C‚O), 9.13–9.06 (d, 2H, Ar), 8.03–8.01 (d, 1H,
Ar), 7.8–7.7 (m, 3H, Ar), 7.6–7.5 (m, 3H, Ar), 7.3–7.2 (m,
2H, Ar), 4.42–4.37 (m, 1H, –CH), 1.46–1.44 (d, 6H, 2-CH3).
M/S m/e: 426, 425, 424, 360.
2.2.5.3. N-(Isopropyl)-9-[(40-carboxy)phenylamino]-acridine-
4-carboxamide hydrochlorde (5b). 0.137 g (0.001 mol) of p-
amino benzoic acid was reacted with 0.3 g (0.001 mol) of N-
(1,1-isopropyl)-9-chloroacridine-4-carboxamide to give orange
powder. Yield 76%, mp 276–278 C. IR (KBr) cm1 mmax:
2925, 1709, 1620, 1579, 1518, 1429, 1354, 1271, 1166, 1105,
1007, 859, 755, 693. NMR (400 MHz, d6-DMSO): 15.50 (s,
1H, NH+), 12–57(s, 1H, NH), 9.07–9.06 (d, 1H, NH–C‚O),
8.96–8.94 (d, 1H, Ar), 8.85–8.83 (d, 1H, Ar), 8.73–8.71 (d,
1H, Ar), 8.50–8.47 (d, 1H, Ar), 8.06–8.04 (d, 2H, Ar), 7.98–
7.94(t, 1H, Ar), 7.91–7.89 (t,1H, Ar), 7.55–7.49 (q, 3H, Ar),
7.37–7.25(t, 1H, Ar), 3.68–3.40 (m, 1H, CH), 1.38–1.36 (d,
6H, 2-CH3). M/S m/e: 401, 400.
2.2.5.4. N-(Isopropyl)-9-[(40-methoxy)phenylamino]acridine-
4-carboxamide (5c). 0.107 g (0.001 mol) of p-anisidine was re-
acted with 0.3 g (0.001 mol) of N-(isopropyl)-9-chloroacridine-
4-carboxamide to give an orange color product. This product
obtained as a pure form as it was treated with dilute sodium
hydroxide. Yield 81%, mp 172–174 C. IR (KBr) cm1 mmax:
3354, 3217, 3050, 2970, 2929, 1618, 1555, 1436, 1243, 1171,
1027, 912. NMR (400 MHz, CDCl3): 12.34 (s, 1H, NH),
9.18–9.12 (t, 2H, Ar), 9.00–8.98 (d, 1H, NH–C‚0), 8.16–
8.14 (d, 1H, Ar), 7.78–7.75 (t, 1H, Ar), 7.62–7.60 (t, 1H, Ar),
7.73–7.26 (t, 2H, Ar), 7.24–7.16 (m, 2H, Ar), 6.84–6.82 (d,
2H, Ar), 4.37–4.35 (m, 1H, –CH), 3.78 (s, 3H, OCH3), 1.44–
1.439 (d, 6H, 2-CH3).
2.2.5.5. N-(Isopropyl)-9-[(20-carboxyl)phenylamino]-acridine-
4-carboxamide hydrochloride (5d). 0.137 g (0.001 mol) of o-
aminobenzoic acid was reacted with 0.3 g (0.001 mol) of N-
(isopropyl)-9-chloroacridine-4-carboxamide to give a yellow
product. Yield 83%, mp 226–229 C. IR (KBr) cm1 mmax:
3449, 3251, 3041, 2971, 1710, 1623, 1567, 1442, 1362, 1205,
1079. NMR (400 MHz, d6-DMSO): 15.79 (s, 1H, NH
+),
12.22 (s, 1H, NH), 9.5–9.4 (d, 1H, NH), 9.17–9.15 (d, 1H,
Ar), 8.5–8.49 (d, 1H, Ar), 8.23–8.21 (t, 2H, Ar), 8.01–7.92
(m, 2H, Ar), 7.57–7.53 (t, 2H, Ar), 7.48–7.43 (m, 2H, Ar),
7.29–7.27 (d, 1H, Ar), 4.43–4.44 (m, 1H, –CH), 1.42–1.40 (d,
6H, 2-CH3).
2.2.5.6. N-(Isopropyl)-9-[(30-chloro)phenylamino]-acridine-4-
carboxamide hydrochloride (5e). 0.11 ml (0.001 mol) of m-chloroaniline was reacted with 0.3 g (0.001 mol) of N-(isopro-
pyl)-9-chloroacridine-4-carboxamide to give a yellow product.
Yield 85%, mp 194–196 C IR (KBr) cm1 mmax: 3396, 3227,
3052, 2971, 2873, 1619, 1573, 1475, 1439, 1324, 1166, 992,
748, 679, 628. NMR (400 MHz, d6-DMSO): 15.31 (s, 1H,
NH+), 12.5 (s, 1H, NH), 9.20–9.18 (d, 2H, Ar), 9.10–9.09
(d, 1H, NH–C‚0), 8.15–8.13 (d, 1H, Ar), 7.87–7.87 (t, 1H,
Ar), 7.85–7.83 (d, 1H, Ar), 7.37–7.33 (t, 2H, Ar), 7.30–7.20
(m, 3H, Ar), 7.20–7.18 (d, 1H, Ar), 4.41–4.36 (m, 1H, CH),
1.46–1.45 (d, 6H, 2-CH3).2.2.5.7. N-(Isopropyl)-9-[(4’-chloro)phenylamino]-acridine-4-
carboxamide hydrochloride (5f). 0.11 ml (0.001 mol) of p-chlo-
roaniline was reacted with 0.3 g (0.001 mol) of N-(isopropyl)-
9-chloroacridine-4-carboxamide to give a yellow product.
Yield 83%, mp 198–202 C. IR (KBr) cm1 mmax: 3349, 3225,
3033, 2871, 2930, 1620, 1554, 1524, 1432, 1169, 1087, 1010,
912, 827, 757, 712. NMR (400 MHz, d6-DMSO): 15.31
(s,1H, NH+), 12.51 (s, 1H, NH), 9.10–9.08 (d, 1H, NH–
C‚0), 8.97–8.95 (d, 1H, Ar), 8.85–8.83(d, 1H, Ar), 8.46–8.44
(d, 1H, Ar), 7.95–7.91 (t, 1H, Ar), 7.87–7.85 (d, 1H, Ar),
7.49–7.37 (m, 6H, Ar), 4.40–4.39 (m, 1H, CH), 1.38–1.36 (d,
6H, 2-CH3).2.2.5.8. N-(Isopropyl)-9-[(4’-methyl)phenylamino]-acridine-4-
carboxamide hydrochloride (5g). 0.107 g (0.001 mol) p-tolui-
dine was reacted with 0.3 g (0.001 mol) of N-(isopropyl)-9-
chloroacridine-4-carboxamide to givea yellow product. Yield
70%, mp 230–232 C. NMR (400 MHz, CDCl3): 14.72 (s,
1H, NH+), 12.46 (s, 1H, NH), 9.23–9.21 (d, 1H, NH–
C‚O), 9.03–9.02 (d, 1H, Ar), 8.94–8.92 (d, 1H, Ar), 8.15–
8.12 (d, 1H, Ar), 7.79–7.75 (t, 1H, Ar), 7.63–7.61 (d, 1H,
Ar), 7.30–7.25 (m, 3H, Ar), 7.21–7.19 (d, 1H, Ar), 7.16–7.13
(t, 2H, Ar), 4.39–4.34 (m, 1H, CH), 2.39–2.34 (s, 3H, –CH3),
1.46–1.42 (d, 6H, 2-CH3).2.3. Anticancer evaluation
2.3.1. Cell lines and culture medium
A-549 (human, small cell lung carcinoma) and HeLa (human,
epithelial cervical cancer) cell cultures were procured from the
National Centre for Cell Sciences (NCCS), Pune, India. Stock
cells were cultured in DMEM supplemented with 10% inacti-
vated fetal bovine serum (FBS), penicillin (100 IU/ml), strepto-
mycin (100 lg/ml) and amphotericin B (5 lg/ml) in a
humidiﬁed atmosphere of 5% CO2 at 37 C until conﬂuent.
The cells were dissociated with TPVG solution (0.2% trypsin,
0.02% EDTA, 0.05% glucose in PBS). The stock cultures were
grown in 25 cm2 culture ﬂasks and all experiments were carried
out in 96 microtitre plates (Tarsons India Pvt. Ltd., Kolkata,
India).2.3.2. Preparation of test solutions
For cytotoxicity studies, each weighed test drug was separately
dissolved in distilled DMSO and the volume was made up with
DMEM supplemented with 2% inactivated FBS to obtain a
stock solution of 1 mg/ml concentration and sterilized by ﬁl-
tration. Serial twofold dilutions were prepared from this for
carrying out cytotoxic studies.
Table 1 Cytotoxic properties of test drugs on A-549 and HeLa cell lines.
Sr. No Test drug CTC50 in lg/ml against
(A-549) cell linea
CTC50 in lg/ml against
(HeLa) cell lineb
1 5a 325.00 700.00
2 5b 370.00 47.50
3 5e 100 130.00
a Dose in lg/ml required to produce 50% inhibition of A-549 cancer cells (n= 2, p< 0.01).
b Dose in lg/ml required to produce 50% inhibition of HeLa cancer cells (n= 2, p< 0.01).
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The monolayer cell culture was trypsinized and the cell count
was adjusted to 1.0 · 105 cells/ml using DMEM medium con-
taining 10% FBS. To each well of the 96 well microtitre plate,
0.1 ml of the diluted cell suspension (approximately 10,000
cells) was added. After 24 h, when a partial monolayer was
formed, the supernatant was ﬂicked off, the monolayer was
washed once with the medium and 100 ll of different test con-
centrations of the test drugs were added on to the partial
monolayer in the microtitre plates. The plates were then incu-
bated at 37 C for 3 days in 5% CO2 atmosphere, and micro-
scopic examination was carried out and observations were
noted every 24 h interval. After 72 h, the drug solutions in
the wells were discarded and 50 ll of MTT in PBS was added
to each well. The plates were gently shaken and incubated for
3 h at 37 C in 5% CO2 atmosphere. The supernatant was re-
moved and 100 ll of propanol was added and the plates were
gently shaken to solubilize the formed formazan. The absor-
bance was measured using a micro plate reader at a wavelength
of 540 nm. The percentage growth inhibition was calculated
using the following formula and the concentration of test drug
needed to inhibit cell growth by 50% (CTC50) values is gener-
ated from the dose-response curves for each cell line (see
Table 1).
% Growth inhibition
¼ 100 Mean OD of individual test group
Mean OD of control group
 
 1003. Results and discussion
9-Aminoacridine-4-carboxamide derivatives have been known
for its potential anti-cancer, MDR inhibitor and anti-inﬂam-
matory activities. We designed, synthesized and characterized
new 9-aminoacridine-4-carboxamide derivatives.
Five steps were involved in the synthesis of N-(isopropyl)-9
amino-4 carboxamide derivative (5a–5g). The lead compound,
N-(isopropyl)-9-chloroacridine-4-carboxamide (4) is a very
new compound and no previous such data are available for
its anticancer activities. The synthesized compounds were puri-
ﬁed by extracting the products with ethanol and diethyl ether
followed by re-crystallized with methanol/ethyl acetate solu-
tion. NMR, IR and mass data reveal the structure of molecules
of newly synthesized acridine derivative. A peak appeared at
about 15 ppm representing the NH+ proton, –NH peak ap-
peared at about 12–13 ppm, –NH–C‚O peak appeared at
about 9–12 ppm and aromatic proton gave their signal in 6–
9 ppm, Whereas OCH3 and CH3 gave their peak at 2–5 ppm.
In IR, the structure was conﬁrmed by functional group identi-ﬁcation. Secondary amine gave its peak value at 3400 cm1. In
carboxamide a peak appears at 3400 and 3200 cm1, ﬁrst peak
represents the secondary amino group whereas a peak at about
3200 is due to –OH peaks generated due to intramolecular
bonding of hydrogen attached to ring nitrogen and oxygen
atom of carbonyl group. Amide group of 9-chloroacridine
gave their peak in at about 1653 cm1 but amide group of 9-
aminoacridine derivative gave their peaks at about
1620 cm1. C–Cl peaks appeared at about 540–785 cm1
whereas C–F peaks appeared at about 1000–1400 cm1. Mass
spectra were recorded only for two compounds and they reveal
the molecular mass of the compounds.
The majority of drugs used for the treatment of cancer to-
day are cytotoxic (cell killing) drugs that work by interfering in
some way with the operation of cell’s DNA. As with any phar-
maceutical, new anticancer drugs are developed in three step
processes i.e., initial discoveries, molecular modiﬁcation of
known compound and development into a useful pharmaceu-
tical. 9-Aminoacridine based drugs shows good anticancer
properties through different pathways (Guo et al., 2009).
DACA is an acridine-4-carboxamide derivative which shows
good anticancer activities against various cancer cell lines
(Adams et al., 2000). Inspired from the anticancer activities
of DACA, we design a new acridine derivative for anticancer
evaluation based upon molecular modiﬁcation. In vitro
anticancer activities of newly synthesized compounds were
determined by using MTT assay (Francis and Rita, 1986).
Lung cancer is mainly caused by smoking and radiation
whereas cervical cancer is mainly caused by human papilloma-
virus which is a sexually transmitted disease. Three compounds
were selected for their anti-cancer evaluation against lung can-
cer (A-549) and cervical cancer (HeLa) cell line. Anticancer
activity was determined by using test drug treated group and
control group. The tested compounds gave different anticancer
activity based upon the position of functional group on aro-
matic ring attached to the acridine ring. Compounds 5a, 5b
and 5e were selected for anticancer evaluation against lung
cancer cell line and cervical cancer cell line to see the effect
of electron withdrawing group and size of electron withdraw-
ing group at position 30 and 40 on aromatic ring attached with
acridine ring. The newly synthesized compound 5a contain
(–CF3) group whereas 5e contains only (–Cl) group at position
30 on aromatic ring attached to acridine ring. The group
(–CF3) is a much bulkier group than (–Cl) and shows less anti-
cancer activity against both the cell lines i.e. A-549 and HeLa
cell lines. The third compound selected for anticancer evalua-
tion is 5b that contains (–COOH) group at para position on
the aromatic ring shows excellent activity against HeLa cell
lines. Compound 5e shows maximum activity against lung can-
cer (A-549) cell line with CTC50 (100 lg/ml). Compounds 5a
64 P. Kumar et al.and 5b also show good activity against lung cancer cell line
with CTC50 (325 and 370 lg/ml), respectively. Compound 5b
shows maximum activity against cervical cancer (HeLa) cell
line with CTC50 (47.50 lg/ml). Compounds 5a and 5e also
show good activity with CTC50 (700 lg/ml and 130 lg/ml)
against cervical cancer, respectively.
Based upon the abovementioned evaluation data against
both cancer cell lines, Structure activity relationship reveals
the following points:
1. 30-substitution by electronegative atom (Cl) gave the maxi-
mum activity against lung cancer cell line than substitution
at 30 position by a bulkier (CF3) group.Figure 2 Cytotoxic effect of compound 5b on A-549 and HeLa
cell lines.
Figure 3 Cytotoxic effect of compound 5e on A-549 and HeLa
cell lines.
Figure 1 Cytotoxic effect of compound 5a on A-549 and HeLa
cell lines.2. Whereas substitution at 40 by (–COOH) group gave maxi-
mum activity against cervical cancer cell line than 30-substi-
tution by electronegative atoms (Cl, CF3) on aromatic ring
attached to acridine ring against HeLa cell lines.
3. By considering the evaluated results of anticancer activities
it can be assumed that substitution at 40-position by
another electron withdrawing group may increase the anti-
cancer activity against both the cell lines.
These newly synthesized derivatives can be further evalu-
ated for in vivo anticancer activities and more new compounds
can be designed.
3.1. Graphical representation of cytotoxic effect of drugs
Figs. 1–3 show cytotoxic effect of test drugs on A-549 and
HeLa cells after 72 h of drug treatment. Cell viability was
determined by MTT assay (n= 2, p< 0.01).
4. Conclusion
In summary, 9-aminoacridine-4carboxamide derivatives have
been designed, synthesized and characterized. Anticancer eval-
uation was done for selected three compounds among the total
synthesized compounds against lung cancer (A-549) cell line
and cervical cancer (HeLa) cell line. Tested compounds shown
good activities against both the cell lines. In future, in vivo anti-
cancer evaluation of these drugs can also be carried out for fur-
ther study.Acknowledgments
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